clobetasol propionate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
prednisone and prednisolone derivatives	4452	25122-46-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: clobetasol 17-propionate clofenazon clobetasol propionate	A derivative of PREDNISOLONE with high glucocorticoid activity and low mineralocorticoid activity. Absorbed through the skin faster than FLUOCINONIDE, it is used topically in treatment of PSORIASIS but may cause marked adrenocortical suppression. Molecular weight: 466.97 Formula: C25H32ClFO5 CLOGP: 3.49 LIPINSKI: 0 HAC: 5 HDO: 1 TPSA: 80.67 ALOGS: -5.05 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

clobetasol 17-propionate
clofenazon
clobetasol propionate

A derivative of PREDNISOLONE with high glucocorticoid activity and low mineralocorticoid activity. Absorbed through the skin faster than FLUOCINONIDE, it is used topically in treatment of PSORIASIS but may cause marked adrenocortical suppression.

Molecular weight: 466.97
Formula: C25H32ClFO5
CLOGP: 3.49
LIPINSKI: 0
HAC: 5
HDO: 1
TPSA: 80.67
ALOGS: -5.05
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.11 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
Dec. 27, 1985	FDA	FOUGERA PHARMS
Feb. 24, 2021	PMDA	Maruho Co., Ltd.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Psoriasis	215.64	12.97	152	10818	86805	63391247
Skin atrophy	154.82	12.97	50	10920	4856	63473196
Squamous cell carcinoma of skin	147.75	12.97	51	10919	6081	63471971
Skin exfoliation	124.82	12.97	83	10887	43019	63435033
Dry skin	89.48	12.97	76	10894	56811	63421241
Dermatitis atopic	82.25	12.97	38	10932	9686	63468366
Pruritus	75.78	12.97	182	10788	361271	63116781
Eczema	69.75	12.97	52	10918	32239	63445813
Product use in unapproved indication	68.56	12.97	116	10854	178964	63299088
Skin fissures	64.90	12.97	34	10936	11354	63466698
Cushing's syndrome	52.91	12.97	14	10956	673	63477379
Neoplasm skin	49.61	12.97	16	10954	1545	63476507
Delayed myelination	45.98	12.97	6	10964	0	63478052
Skin haemorrhage	43.34	12.97	25	10945	10069	63467983
Product dose omission issue	36.71	12.97	106	10864	234207	63243845
Steroid diabetes	35.90	12.97	12	10958	1296	63476756
Biliary sepsis	35.64	12.97	11	10959	920	63477132
Skin plaque	34.11	12.97	20	10950	8300	63469752
Ochronosis	33.64	12.97	6	10964	41	63478011
Erythema	29.94	12.97	82	10888	175669	63302383
Injection site alopecia	29.04	12.97	5	10965	27	63478025
Cushingoid	28.62	12.97	18	10952	8467	63469585
Contraindicated product administered	27.08	12.97	3	10967	217645	63260407
Skin burning sensation	26.36	12.97	20	10950	12714	63465338
Dermatitis bullous	26.10	12.97	17	10953	8491	63469561
Injection site pain	25.62	12.97	64	10906	129736	63348316
Resting tremor	24.39	12.97	8	10962	815	63477237
Psoriatic arthropathy	23.43	12.97	50	10920	91470	63386582
Dermatitis	23.30	12.97	21	10949	16937	63461115
Infusion related reaction	22.87	12.97	7	10963	245514	63232538
Alopecia scarring	22.66	12.97	5	10965	110	63477942
Synovitis	22.21	12.97	3	10967	186915	63291137
Drug intolerance	22.06	12.97	13	10957	308648	63169404
Product container issue	21.64	12.97	9	10961	1784	63476268
Bronchiolitis obliterans syndrome	21.61	12.97	5	10965	137	63477915
Pain of skin	21.32	12.97	17	10953	11617	63466435
Skin striae	20.23	12.97	8	10962	1393	63476659
Necrotising fasciitis	19.99	12.97	10	10960	3031	63475021
Pemphigus	19.50	12.97	4	10966	183722	63294330
Systemic lupus erythematosus	19.37	12.97	6	10964	208912	63269140
Papule	19.01	12.97	12	10958	5679	63472373
Glossodynia	18.76	12.97	4	10966	178872	63299180
Toxicity to various agents	18.25	12.97	10	10960	247240	63230812
Cutaneous lupus erythematosus	18.07	12.97	9	10961	2703	63475349
Rash pruritic	18.06	12.97	35	10935	59764	63418288
Skin abrasion	17.88	12.97	14	10956	9315	63468737
Cortisol decreased	17.60	12.97	7	10963	1237	63476815
Incorrect product administration duration	17.26	12.97	15	10955	11531	63466521
Drug ineffective	16.42	12.97	262	10708	1044503	62433549
Rheumatoid arthritis	16.35	12.97	12	10958	253807	63224245
Seborrhoeic keratosis	16.28	12.97	8	10962	2334	63475718
Pustular psoriasis	16.07	12.97	10	10960	4616	63473436
Infected dermal cyst	15.72	12.97	5	10965	462	63477590
Arthropathy	15.25	12.97	11	10959	234781	63243271
Pterygium	15.02	12.97	4	10966	197	63477855
Nasal polypectomy	15.01	12.97	3	10967	40	63478012
Poikiloderma	14.50	12.97	4	10966	225	63477827
Burning sensation	14.23	12.97	30	10940	54377	63423675
Rash pustular	14.11	12.97	11	10959	7271	63470781
Lipohypertrophy	13.98	12.97	5	10965	660	63477392
Skin infection	13.93	12.97	15	10955	14987	63463065
Product physical consistency issue	13.74	12.97	5	10965	694	63477358
Hirsutism	13.53	12.97	6	10964	1389	63476663
Terminal ileitis	13.42	12.97	5	10965	741	63477311
Skin weeping	13.38	12.97	5	10965	748	63477304
Skin swelling	13.35	12.97	8	10962	3451	63474601
Therapeutic response shortened	13.05	12.97	13	10957	11875	63466177

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Psoriasis	153.14	16.82	89	5616	38723	34912503
Skin exfoliation	100.47	16.82	60	5645	27372	34923854
Dermatitis atopic	95.18	16.82	35	5670	5312	34945914
Dry skin	67.08	16.82	49	5656	31238	34919988
Pruritus	65.54	16.82	97	5608	141884	34809342
Human herpesvirus 8 infection	48.86	16.82	14	5691	961	34950265
Rash	47.51	16.82	109	5596	222643	34728583
Skin fissures	43.86	16.82	20	5685	5239	34945987
Eczema	42.06	16.82	30	5675	18406	34932820
Folliculitis	30.80	16.82	15	5690	4551	34946675
Drug ineffective	26.46	16.82	145	5560	456606	34494620
Product dose omission issue	25.88	16.82	59	5646	119652	34831574
Cushing's syndrome	25.57	16.82	7	5698	406	34950820
Psoriatic arthropathy	25.41	16.82	23	5682	19775	34931451
Skin atrophy	24.10	16.82	10	5695	2087	34949139
Pemphigoid	21.85	16.82	15	5690	8651	34942575
Skin haemorrhage	21.83	16.82	12	5693	4666	34946560
Death	20.42	16.82	21	5684	398028	34553198
Cellulitis	19.91	16.82	33	5672	52918	34898308
Erythema	19.44	16.82	44	5661	88736	34862490
Angioplasty	19.41	16.82	7	5698	1003	34950223
Product use in unapproved indication	19.15	16.82	52	5653	117447	34833779
Necrotising fasciitis	18.63	16.82	10	5695	3712	34947514
Adrenal suppression	18.35	16.82	6	5699	641	34950585

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Psoriasis	217.12	13.94	149	12403	89438	79642398
Skin atrophy	180.48	13.94	57	12495	5661	79726175
Cushing's syndrome	149.13	13.94	34	12518	961	79730875
Squamous cell carcinoma of skin	120.93	13.94	54	12498	13979	79717857
Skin exfoliation	115.63	13.94	84	12468	55016	79676820
Dermatitis atopic	87.61	13.94	39	12513	10017	79721819
Pruritus	85.19	13.94	190	12362	394458	79337378
Skin fissures	83.79	13.94	41	12511	13032	79718804
Dry skin	79.95	13.94	74	12478	67921	79663915
Eczema	67.47	13.94	54	12498	40764	79691072
Incorrect product administration duration	63.27	13.94	33	12519	11989	79719847
Product use in unapproved indication	55.55	13.94	122	12430	250237	79481599
Skin haemorrhage	46.77	13.94	27	12525	11954	79719882
Delayed myelination	46.54	13.94	6	12546	0	79731836
Neoplasm skin	46.46	13.94	15	12537	1596	79730240
Necrotising fasciitis	44.93	13.94	21	12531	6029	79725807
Ochronosis	32.35	13.94	6	12546	58	79731778
Adrenal suppression	32.25	13.94	11	12541	1388	79730448
Pemphigoid	31.31	13.94	23	12529	15292	79716544
Cushingoid	30.71	13.94	19	12533	9533	79722303
Biliary sepsis	30.69	13.94	11	12541	1606	79730230
Rash	29.38	13.94	173	12379	578185	79153651
Skin striae	29.03	13.94	11	12541	1877	79729959
Steroid diabetes	28.63	13.94	13	12539	3493	79728343
Product dose omission issue	27.87	13.94	94	12458	247443	79484393
Cortisol decreased	27.53	13.94	11	12541	2161	79729675
Chorioretinopathy	27.24	13.94	11	12541	2220	79729616
Erythema	27.11	13.94	87	12465	223203	79508633
Adrenal insufficiency	25.98	13.94	27	12525	28460	79703376
Human herpesvirus 8 infection	25.82	13.94	9	12543	1211	79730625
Skin burning sensation	25.05	13.94	19	12533	13253	79718583
Toxicity to various agents	23.68	13.94	19	12533	421521	79310315
Psoriatic arthropathy	23.21	13.94	43	12509	77956	79653880
Resting tremor	20.31	13.94	8	12544	1513	79730323
Injection site pain	19.93	13.94	55	12497	129783	79602053
Drug interaction	18.40	13.94	23	12529	415160	79316676
Tinea capitis	18.25	13.94	3	12549	13	79731823
Alopecia scarring	17.97	13.94	4	12548	101	79731735
Hypothalamic pituitary adrenal axis suppression	17.81	13.94	5	12547	330	79731506
Dermatitis bullous	17.69	13.94	16	12536	14229	79717607
Dermatitis exfoliative generalised	17.39	13.94	12	12540	7229	79724607
Dermatitis	17.31	13.94	19	12533	21302	79710534
Rash pruritic	17.09	13.94	36	12516	71593	79660243
Lipohypertrophy	16.73	13.94	6	12546	878	79730958
Death	16.41	13.94	41	12511	566473	79165363
Neuralgia	16.22	13.94	23	12529	33361	79698475
Cutaneous T-cell lymphoma	15.90	13.94	8	12544	2695	79729141
Pain of skin	15.43	13.94	15	12537	14598	79717238
Off label use	15.17	13.94	213	12339	907002	78824834
Chemical burn	15.00	13.94	5	12547	588	79731248
Beta haemolytic streptococcal infection	14.71	13.94	7	12545	2090	79729746
Cellulitis	14.61	13.94	44	12508	109016	79622820
Inappropriate schedule of product administration	14.36	13.94	50	12502	133578	79598258
Hirsutism	14.12	13.94	6	12546	1376	79730460

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	D07AD01	DERMATOLOGICALS CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS CORTICOSTEROIDS, PLAIN Corticosteroids, very potent (group IV)
ATC	D07CD01	DERMATOLOGICALS CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS Corticosteroids, very potent, combinations with antibiotics
FDA MoA	N0000175450	Corticosteroid Hormone Receptor Agonists
FDA EPC	N0000175576	Corticosteroid
MeSH PA	D000893	Anti-Inflammatory Agents
MeSH PA	D005938	Glucocorticoids
MeSH PA	D006728	Hormones
CHEBI has role	CHEBI:35472	anti-inflammatory drugs
CHEBI has role	CHEBI:131809	smoothened receptor agonists

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Atopic dermatitis	indication	24079001	DOID:3310
Contact dermatitis	indication	40275004	DOID:2773
Seborrheic dermatitis	indication	50563003	DOID:8741
Nummular eczema	indication	81418003
Plaque psoriasis	indication	200965009
Scalp psoriasis	indication	238608008
Dermatosis of scalp	indication	402694007	DOID:3136
Inflammatory dermatosis	indication	703938007
Folliculitis	contraindication	13600006	DOID:4409
Glaucoma	contraindication	23986001	DOID:1686
Diabetes mellitus	contraindication	73211009	DOID:9351
Hyperglycemia	contraindication	80394007	DOID:4195
Open wound	contraindication	125643001
Skin striae	contraindication	201066002
Adrenal cortical hypofunction	contraindication	386584007	DOID:10493
Atrophoderma	contraindication	399979006
Peripheral vascular disease	contraindication	400047006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.48	acidic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
0.05%	OLUX E	MYLAN	N022013	Jan. 12, 2007	RX	AEROSOL, FOAM	TOPICAL	8962000	Aug. 31, 2025	TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES
0.05%	OLUX E	MYLAN	N022013	Jan. 12, 2007	RX	AEROSOL, FOAM	TOPICAL	8460641	Nov. 5, 2028	TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES
0.025%	IMPOYZ	PRIMUS PHARMS	N209483	Nov. 28, 2017	RX	CREAM	TOPICAL	10064875	Aug. 31, 2030	PSORIASIS
0.025%	IMPOYZ	PRIMUS PHARMS	N209483	Nov. 28, 2017	RX	CREAM	TOPICAL	10064875	Aug. 31, 2030	TREATMENT OF MODERATE PLAQUE PSORIASIS
0.025%	IMPOYZ	PRIMUS PHARMS	N209483	Nov. 28, 2017	RX	CREAM	TOPICAL	10064875	Aug. 31, 2030	TREATMENT OF PLAQUE PSORIASIS
0.025%	IMPOYZ	PRIMUS PHARMS	N209483	Nov. 28, 2017	RX	CREAM	TOPICAL	10064875	Aug. 31, 2030	TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER
0.025%	IMPOYZ	PRIMUS PHARMS	N209483	Nov. 28, 2017	RX	CREAM	TOPICAL	10064875	Aug. 31, 2030	TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.
0.025%	IMPOYZ	PRIMUS PHARMS	N209483	Nov. 28, 2017	RX	CREAM	TOPICAL	10588914	Aug. 31, 2030	TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER
0.025%	IMPOYZ	PRIMUS PHARMS	N209483	Nov. 28, 2017	RX	CREAM	TOPICAL	9956231	Aug. 31, 2030	PLAQUE PSORIASIS
0.025%	IMPOYZ	PRIMUS PHARMS	N209483	Nov. 28, 2017	RX	CREAM	TOPICAL	9956231	Aug. 31, 2030	PSORIASIS
0.025%	IMPOYZ	PRIMUS PHARMS	N209483	Nov. 28, 2017	RX	CREAM	TOPICAL	9956231	Aug. 31, 2030	TREATMENT OF MODERATE PLAQUE PSORIASIS
0.025%	IMPOYZ	PRIMUS PHARMS	N209483	Nov. 28, 2017	RX	CREAM	TOPICAL	9956231	Aug. 31, 2030	TREATMENT OF PLAQUE PSORIASIS
0.025%	IMPOYZ	PRIMUS PHARMS	N209483	Nov. 28, 2017	RX	CREAM	TOPICAL	9956231	Aug. 31, 2030	TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER
0.025%	IMPOYZ	PRIMUS PHARMS	N209483	Nov. 28, 2017	RX	CREAM	TOPICAL	9956231	Aug. 31, 2030	TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Glucocorticoid receptor	Nuclear hormone receptor	P04150	GCR_HUMAN	AGONIST	Ki	9.18	DRUG MATRIX	CHEMBL
Annexin A1	Cytosolic other	P04083	ANXA1_HUMAN				WOMBAT-PK
Bile salt export pump	Transporter	O95342	ABCBB_HUMAN		IC50	5.07	CHEMBL
Cytochrome P450 3A5	Enzyme	P20815	CP3A5_HUMAN		IC50	7.68	CHEMBL
Androgen receptor	Transcription factor		ANDR_RAT		Ki	5.60	DRUG MATRIX
Progesterone receptor	Transcription factor		Q690N0_BOVIN		Ki	8.82	DRUG MATRIX
Glucocorticoid receptor	Transcription factor		GCR_RAT		IC50	8.50	CHEMBL
Bile salt export pump	Transporter		ABCBB_RAT		IC50	4.46	CHEMBL

External reference:

ID	Source
D01272	KEGG_DRUG
4018898	VUID
N0000179087	NUI
4018898	VANDF
4019684	VANDF
CHEBI:31414	CHEBI
CHEBI:205919	CHEBI
XRD	PDB_CHEM_ID
CHEMBL1159650	ChEMBL_ID
DB01013	DRUGBANK_ID
7062	IUPHAR_LIGAND_ID
779619577M	UNII
32798	PUBCHEM_CID
DB11750	DRUGBANK_ID
21245	RXNORM
300	MMSL
4471	MMSL
72591	MMSL
002203	NDDF
004480	NDDF
32197004	SNOMEDCT_US
419129004	SNOMEDCT_US
48614001	SNOMEDCT_US
C0055895	UMLSCUI
D002990	MESH_DESCRIPTOR_UI
C0008992	UMLSCUI
3154	INN_ID
25122-41-2	SECONDARY_CAS_RN
5311051	PUBCHEM_CID
ADN79D536H	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Clobetasol Propionate	HUMAN PRESCRIPTION DRUG LABEL	1	0168-0162	OINTMENT	0.50 mg	TOPICAL	ANDA	20 sections
Clobetasol Propionate	HUMAN PRESCRIPTION DRUG LABEL	1	0168-0163	CREAM	0.50 mg	TOPICAL	ANDA	20 sections
Clobetasol Propionate	HUMAN PRESCRIPTION DRUG LABEL	1	0168-0269	SOLUTION	0.50 mg	TOPICAL	ANDA	18 sections
Clobetasol Propionate	HUMAN PRESCRIPTION DRUG LABEL	1	0168-0293	GEL	0.50 mg	TOPICAL	ANDA	20 sections
Clobetasol Propionate (emollient)	HUMAN PRESCRIPTION DRUG LABEL	1	0168-0301	CREAM	0.50 mg	TOPICAL	ANDA	25 sections
Clobex	HUMAN PRESCRIPTION DRUG LABEL	1	0299-3847	SHAMPOO	0.05 g	TOPICAL	NDA	25 sections
Clobex	HUMAN PRESCRIPTION DRUG LABEL	1	0299-3847	SHAMPOO	0.05 g	TOPICAL	NDA	25 sections
Clobex	HUMAN PRESCRIPTION DRUG LABEL	1	0299-3848	LOTION	0.05 g	TOPICAL	NDA	25 sections
CLOBEX	HUMAN PRESCRIPTION DRUG LABEL	1	0299-3849	SPRAY	0.05 g	TOPICAL	NDA	26 sections
CLOBEX	HUMAN PRESCRIPTION DRUG LABEL	1	0299-3849	SPRAY	0.05 g	TOPICAL	NDA	26 sections
Clobetasol Propionate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8055	AEROSOL, FOAM	0.50 mg	TOPICAL	NDA authorized generic	27 sections
Clobetasol Propionate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8055	AEROSOL, FOAM	0.50 mg	TOPICAL	NDA authorized generic	27 sections
OLUX-E	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8147	AEROSOL, FOAM	0.50 mg	TOPICAL	NDA	26 sections
OLUX-E	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8147	AEROSOL, FOAM	0.50 mg	TOPICAL	NDA	26 sections
clobetasol propionate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8167	AEROSOL, FOAM	0.50 mg	TOPICAL	NDA authorized generic	26 sections
OLUX	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8182	AEROSOL, FOAM	0.50 mg	TOPICAL	NDA	26 sections
Temovate Scalp Application	HUMAN PRESCRIPTION DRUG LABEL	1	0462-0269	SOLUTION	0.50 mg	TOPICAL	NDA	20 sections
Temovate	HUMAN PRESCRIPTION DRUG LABEL	1	0462-0293	GEL	0.50 mg	TOPICAL	NDA	21 sections
Clobetasol Propionate	HUMAN PRESCRIPTION DRUG LABEL	1	0472-0400	CREAM	0.50 mg	TOPICAL	ANDA	19 sections
Clobetasol Propionate	HUMAN PRESCRIPTION DRUG LABEL	1	0472-0402	SOLUTION	0.50 mg	TOPICAL	ANDA	13 sections
Clobetasol Propionate	HUMAN PRESCRIPTION DRUG LABEL	1	0472-0403	SHAMPOO	0.05 g	TOPICAL	ANDA	18 sections
Clobetasol Propionate	HUMAN PRESCRIPTION DRUG LABEL	1	0472-0404	LOTION	0.05 g	TOPICAL	ANDA	17 sections
CLOBETASOL PROPIONATE	HUMAN PRESCRIPTION DRUG LABEL	1	0591-4039	SPRAY	0.05 g	TOPICAL	NDA authorized generic	26 sections
CLOBETASOL PROPIONATE	HUMAN PRESCRIPTION DRUG LABEL	1	0591-4039	SPRAY	0.05 g	TOPICAL	NDA authorized generic	26 sections
Clobetasol Propionate	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0656	OINTMENT	0.50 mg	TOPICAL	ANDA	19 sections
Clobetasol Propionate	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0656	OINTMENT	0.50 mg	TOPICAL	ANDA	19 sections
clobetasol propionate	HUMAN PRESCRIPTION DRUG LABEL	1	0781-7137	SHAMPOO	0.05 g	TOPICAL	NDA authorized generic	25 sections
Temovate	HUMAN PRESCRIPTION DRUG LABEL	1	10337-162	OINTMENT	0.50 mg	TOPICAL	ANDA	21 sections
Temovate	HUMAN PRESCRIPTION DRUG LABEL	1	10337-162	OINTMENT	0.50 mg	TOPICAL	ANDA	21 sections
Temovate	HUMAN PRESCRIPTION DRUG LABEL	1	10337-163	CREAM	0.50 mg	TOPICAL	ANDA	21 sections